Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34358
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 18056/20254 (89%)
造访人次 : 480556      在线人数 : 711
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34358


    標題: Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis
    作者: Peng, Tzu-Rong
    Lin, Hung-Hong
    Tsai, Fang-Pei
    Wu, Ta-Wei
    貢獻者: Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Pharm
    Chia Nan Univ Pharm & Sci, Dept Pharm
    Taipei Med Univ, Coll Pharm, Sch Pharm
    關鍵字: immune checkpoint inhibitors
    non-small cell lung cancer
    overall survival
    progression-free survival
    日期: 2021
    上傳時間: 2023-11-11 11:46:41 (UTC+8)
    出版者: WILEY
    摘要: Objective Currently, several immune checkpoint inhibitors (ICIs) treatment for advanced non-small-cell lung cancer (NSCLC) have been investigated; their overall efficacy and safety remain unclear. Methods We searched electronic databases such as PubMed, EMBASE, and the Cochrane library. The randomized controlled trials (RCTs) that compared ICIs with or without chemotherapy to chemotherapy in advanced NSCLC. We collected and compaired thier parameters, including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (TRAEs) of grade >= 3. Results A total of 15 RCTs involving 8869 patients with NSCLC were included. Pembrolizumab plus platinum-based chemotherapy had higher OS and PFS than platinum-based chemotherapy (hazard ratio [HR] 0.55, 95% CI 0.46-0.67; HR 0.54, 95% CI 0.41-0.70, respectively). Pembrolizumab plus platinum-based chemotherapy had higher ranked ORR than platinum-based chemotherapy (odds ratio [OR] 2.92, 95% CI 1.99-4.22). In terms of OS, atezolizumab, pembrolizumab plus platinum-based chemotherapy, and nivolumab plus ipilimumab ranked as the best treatments for patients with programmed death-ligand 1 (PD-L1) expression levels of >= 50%, 1-49%, and <1%, respectively. In terms of PFS, pembrolizumab plus platinum-based chemotherapy ranked as the best treatment for patients with any PD-L1 expression levels. However, ipilimumab plus platinum-based chemotherapy, nivolumab plus platinum-based chemotherapy, and atezolizumab plus platinum-based chemotherapy have higher TRAEs of grade >= 3 than platinum-based chemotherapy. Conclusions Pembrolizumab plus platinum-based chemotherapy prevailed in rank in OS, PFS, and ORR benefit. The TRAEs of pembrolizumab plus platinum-based chemotherapy were more than ICI monotherapy and chemotherapy.
    關聯: THORAC CANCER, v.12, n.21, pp.2873-2885
    显示于类别:[藥學系(所)] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    1759-7714.14148.pdf1884KbAdobe PDF53检视/开启
    index.html0KbHTML130检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈